Rezultati pretraživanja
  1. prije 12 sati

    highlights the complexities of communicating with our patients and how if we are to advocate for our patients effectively it involves collaborating with the whole MDT.

    Prikaži ovu nit
  2. prije 12 sati

    Patients who swapped to Emicizumab from FVIII prophylaxis had a 68% reduction in bleeds (comparing their own bleeds, pre and post switch).

  3. prije 12 sati

    Thanks for share, a lot of actually healthcare providers missed this symposium because "they are not healthcare providers" despite years of manage emicizumab 🤨 hope this discrimination change next years

  4. prije 12 sati

    Presenting the start of my PhD-project at

  5. Poster at on 81 PWH in UK who switched to EHL FVIII (Elocta). ABR decreased from median of 3.2 to 1.7 and AJBR decreased from 1.6 to 0.8. CFC units used decreased by 16%.

  6. prije 9 sati

    Had a pretty great meeting today, rare that a meeting sorts out work rather than creates it. It was at , the Women with Bleeding Disorders group. We finalised a paper, developed principles of care & planned our next steps.I'm privileged to work with such a great group.

  7. prije 14 sati

    Again and again at we hear the question, why is expression following so much more durable than ? Again and again we hear in reply.....

  8. Prepared my talk for the meeting on future diagnostics for platelet disorders. Will ask questions tomorrow about ethics related to genetic testing ! Hope to get audience feedback

  9. prije 12 sati

    uniQure will have six presentations at this evening’s poster session, beginning at 18:30 CET. You can access all six posters now on our website.

  10. Speaking at the Uniqure symposium at I asked the audience questions. On duration of Gene Therapy factor expression, most popular answer was at least 10 years. On factor expression, 47% wanted 20% to 40 % 1/

    Prikaži ovu nit
  11. We are excited to present one of the top scoring abstracts! Check out our EAHAD poster this evening to learn more about FVII Deficiency & see data from our SIG-009 pre-clinical program. You can swing by during the Welcome Reception (6:30-7:30pm local time).

  12. prije 11 sati

    Our man at EAHAD ! Well done ⁦⁩ ⁦⁩ ⁦ # ankles

  13. prije 14 sati

    At last year’s EAHAD, told us they wanted interactive face-to-face educational activities, with patient-focused content. Read the results here:

  14. prije 6 sati

    you're nobody if you haven't taken THE PHOTO

  15. prije 7 sati

    Packed day at - still time for this though.... Sorry

  16. prije 8 sati

    Congrats to from Prof Gormley group for top scoring abstract at from the iPATH study. Great work, credit to the enthusiastic participation of our patients in this study

  17. prije 10 sati

    best photo of a pooch photo bombing!

  18. Dr. Brahm Goldstein, : “Today, we presented updated clinical trial data confirming the efficacy and safety of rVIII-SingleChain and rFIX-Fusion Protein in recent Phase 3 clinical trials.”

  19. Catherine Lambert : "Recent real-life data on FIX confirm the efficacy and safety of EHL-rFIXs that were demonstrated in pivotal trials. In addition, they provide new insights on the benefits&new opportunities in the use of EHL-rFIXs in specific settings."

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.